Literature DB >> 8640848

Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro.

G Pawelec1, A Rehbein, E Schlotz, P da Silva.   

Abstract

Using a modification of the autologous mixed lymphocyte/tumour cell culture (MLTC), it is demonstrated here that lymphocytes from chronic-phase myelogenous leukaemia (CML) patients (n = 58), but not from their HLA-identical siblings, proliferated upon coculture with autologous tumour cells. However, in most cases, the level of proliferation measured was low (stimulation index < 3, n = 37). This was most likely related to the amount of interleukin-10 (IL-10) released into the culture medium by the CML cells, because addition of neutralizing anti_IL-10 serum to MLTC markedly enhanced proliferative responses. In addition, supplementation of media with IL-1 alpha further enhanced proliferative responses and a combination of anti-IL-10 serum and IL-1 alpha was more effective than either agent alone. Only HLA-DR-matched CML cells, but not HLA-DR-mismatched CML cells or matched or mismatched PBMC restimulated proliferation of IL-2-dependent T cell lines derived from MTLC supplemented with IL-1 alpha and anti-IL-10 serum. The responding cells under these conditions were predominantly CD4+ and secreted IL-2, and interferon gamma; some secreted IL-4, but none secreted IL-10. These data therefore suggest the existence of an HLA-DR-restricted DTH/Th1-type of tumour-specific immunity in CML patients, which may be down-regulated in vitro by excessive secretion of IL-10 together with depressed secretion of IL-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640848     DOI: 10.1007/s002620050270

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

1.  Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.

Authors:  Zuzana Humlová; Hana Klamová; Ivana Janatková; Karin Malíčková; Petra Králíková; Ivan Sterzl; Zdeněk Roth; Eva Hamšíková; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2010-12-12

2.  Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

Authors:  Cesarina Giallongo; Nunziatina Parrinello; Daniele Tibullo; Piera La Cava; Alessandra Romano; Annalisa Chiarenza; Ignazio Barbagallo; Giuseppe A Palumbo; Fabio Stagno; Paolo Vigneri; Francesco Di Raimondo
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.